<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In 1999 a working group of the World Health Organization (WHO) published a revised classification for <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>): RA, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (RC+Dys), <z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB I</z:e> and II, del (5q) syndrome, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> unclassifiable </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t were excluded </plain></SENT>
<SENT sid="2" pm="."><plain>Standard French-American-British (FAB) and new WHO classifications have been compared in a series of patients (n = 431) from a single center, analyzing morphologic, clinical, and cytogenetic data </plain></SENT>
<SENT sid="3" pm="."><plain>According to the WHO findings, dysgranulocytopoiesis or dysmegakaryocytopoiesis only were found in 26% of patients with less than 5% medullary blasts </plain></SENT>
<SENT sid="4" pm="."><plain>These patients are thus unclassified and should remain in the subgroups RA and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Splitting of <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> into 2 subgroups according to blast count was supported by a trend to a statistically significant difference in the single-center study population </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> whose white blood cell counts are above 13 000/microL may be excluded from the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> classification, as warranted by WHO, but a redistribution of patients with dysplastic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> according to medullary blast count leads to more <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> in other WHO subgroups </plain></SENT>
<SENT sid="7" pm="."><plain>Although the natural courses of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) with <z:mpath ids='MPATH_589'>dysplasia</z:mpath> are different, comparable median survival durations after treatment in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> were in favor of the proposed 20% medullary blast threshold for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The homogeneity of subgroups was studied by evaluating prognostic scores </plain></SENT>
<SENT sid="9" pm="."><plain>A significant shift into lower IPSS risk groups was evident in the new classification </plain></SENT>
<SENT sid="10" pm="."><plain>These data cannot provide evidence for the new WHO proposal, which should not be adopted for routine clinical use at present </plain></SENT>
<SENT sid="11" pm="."><plain>Some of its aspects can provide a starting point for further studies involving refined cytogenetics and clinical results </plain></SENT>
</text></document>